Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, noviembre 18
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Filana Therapeutics Inc
FLNA
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.4809
0.0109
2.32%
al cierre: Nov 17, 4:00 PM EST
$0.4800
-0.0009
-0.19%
After hour: 4:00 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Filana Therapeutics Financials
Filana Therapeutics (FLNA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Filana Therapeutics Q3 EPS $(0.22) Beats $(0.24) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Filana Therapeutics Sees H2 2026 Net Cash Used In Operations Of $11M-$15M; Year-End Cash $38M-$42M
Benzinga Newsdesk
PRO
Filana Therapeutics Expects Patient Screening In Phase 2a Study Of Simufilam In TSC-Related Epilepsy To Begin By Q1 2027, Following FDA Lift Of Clinical Hold In September
Benzinga Newsdesk
PRO
Filana Therapeutics Q3 GAAP EPS $(0.22) vs $(0.22) YoY
Benzinga Newsdesk
PRO
Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 18.18 percent. This is a 80.43 percent increase over losses of $(0.92) per share
Benzinga Newsdesk
PRO
Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 56.25 percent increase over losses of $(0.48) per share from
Benzinga Newsdesk